AI-Powered Discovery of T-Cell-Receptor-Based Cancer Immunotherapies
In-house generation of massive TCR-target interaction datasets using cutting-edge
high-throughput screening techniques
In silico predictions of TCR-target interactions through deep learning models trained on our proprietary datasets
Discovery of novel tumour targets shared across patients and safe and effective target-specific TCRs
CEO and CO-FOUNDER
Federico is a computational biologist with deep expertise in mathematical modelling and molecular biophysics. He holds a PhD in Molecular and Computational Oncology from the University of Oxford and has previously worked at the World Health Organization assessing cancer prevention strategies.
CTO and CO-FOUNDER
Andrea is an experienced Machine Learning Scientist. He holds a PhD in Bio-Inspired Computation from the University of Birmingham and has several years of hands-on experience building cutting-edge AI. He has previously led the ML team at Portent.io (acquired by Yougov) and has worked at the European Space Agency, Honda Research Institute and Vodafone.
HEAD of CELL BIOLOGy
Amanda is an experienced cell biologist. She holds a PhD in Biochemistry and Molecular Biology from Monash University (Australia) and she has previously developed TCR bi-specifics for the treatment of cancers and infectious diseases at Immunocore, a top TCR company.
MACHINE LEARNING SCIENTIST
Ryan is an experienced Machine Learning Scientist with a PhD in Chemistry from Cornell University. He joined Exogene from the Machine Learning Group at Bayer and his recent work there was published at ICML. He previously worked at Intel and in his spare time he participates in machine learning competitions.
Ricardo is a world expert in wet-lab methods for high-throughput screening of TCR-target pairs. He is a Principal Investigator at the University of Oxford and he has published in high-profile journals such as Nature Immunology, Cell and PNAS.
Alasdair has extensive experience negotiating and managing AI-driven co-development partnerships in the biopharmaceutical industry. He is a Founding Partner at Selvedge Venture and former director of deep-tech venture investments at Leaps by Bayer.